OptiNose XHANCE OKd as 1st, Only Med for Chronic Rhinosinusitis

 ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps

Clinical trial program also showed reduction in sinus inflammation and in acute exacerbations, which frequently result in use of antibiotics

XHANCE uses the proprietary Exhalation Delivery System to enable deposition of a proven steroid in target areas of inflammation deep in the nose not typically reached by standard nasal sprays

Chronic sinusitis affects approximately 30 million adults in the U.S.

https://www.globenewswire.com/news-release/2024/03/15/2847277/0/en/XHANCE-Approved-by-FDA-as-First-and-Only-Medication-Indicated-for-Treatment-of-Adults-with-Chronic-Rhinosinusitis-without-Nasal-Polyps.html